ECSP045065A - Queratinocitos utilizables como sustancia biológicamente activa en el tratamiento de heridas - Google Patents

Queratinocitos utilizables como sustancia biológicamente activa en el tratamiento de heridas

Info

Publication number
ECSP045065A
ECSP045065A EC2004005065A ECSP045065A ECSP045065A EC SP045065 A ECSP045065 A EC SP045065A EC 2004005065 A EC2004005065 A EC 2004005065A EC SP045065 A ECSP045065 A EC SP045065A EC SP045065 A ECSP045065 A EC SP045065A
Authority
EC
Ecuador
Prior art keywords
queratinocits
active substance
biologically active
wound treatment
treatment
Prior art date
Application number
EC2004005065A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045065A publication Critical patent/ECSP045065A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0629—Keratinocytes; Whole skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60—Materials for use in artificial skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Botany (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención trata de queratinocitos novedosos que se puede cultivar in vitro y el uso ventajoso de esos para la fabricación de un producto, que puede ser usado para el tratamiento de heridas agudas y crónicas.
EC2004005065A 2001-10-17 2004-04-15 Queratinocitos utilizables como sustancia biológicamente activa en el tratamiento de heridas ECSP045065A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10151296A DE10151296A1 (de) 2001-10-17 2001-10-17 Keratinozyten verwendbar als biologisch aktive Substanz bei der Behandlung von Wunden

Publications (1)

Publication Number Publication Date
ECSP045065A true ECSP045065A (es) 2004-05-28

Family

ID=7702826

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005065A ECSP045065A (es) 2001-10-17 2004-04-15 Queratinocitos utilizables como sustancia biológicamente activa en el tratamiento de heridas

Country Status (30)

Country Link
US (3) US7247478B2 (es)
EP (1) EP1440148B1 (es)
JP (1) JP4476625B2 (es)
KR (1) KR101019916B1 (es)
CN (1) CN100432220C (es)
AR (1) AR036827A1 (es)
AT (1) ATE474039T1 (es)
AU (1) AU2002349352B2 (es)
BR (1) BR0213282A (es)
CA (1) CA2461141C (es)
CO (1) CO5580844A2 (es)
DE (2) DE10151296A1 (es)
DK (1) DK1440148T3 (es)
EA (1) EA009073B1 (es)
EC (1) ECSP045065A (es)
ES (1) ES2345767T3 (es)
HR (1) HRP20040347B1 (es)
HU (1) HU228887B1 (es)
IL (2) IL161442A0 (es)
MX (1) MXPA04003487A (es)
MY (1) MY137828A (es)
NO (1) NO334974B1 (es)
NZ (1) NZ532899A (es)
PE (1) PE20030627A1 (es)
PL (1) PL367338A1 (es)
RS (1) RS30104A (es)
UA (1) UA81398C2 (es)
UY (1) UY27486A1 (es)
WO (1) WO2003033686A2 (es)
ZA (1) ZA200402306B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP2481287B1 (en) * 2003-08-01 2016-07-20 Stratatech Corporation Human skin equivalents expressing exogenous polypeptides
US20060019237A1 (en) * 2004-07-20 2006-01-26 The Regents Of The University Of California In vitro wound healing assay and device
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
WO2009052429A1 (en) * 2007-10-19 2009-04-23 Jarrell John D Novel compositions and related methods, coatings, and articles
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
WO2009144720A1 (en) 2008-05-27 2009-12-03 Pluristem Ltd. Methods of treating inflammatory colon diseases
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN107011345A (zh) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
EP2580327B1 (en) * 2010-06-09 2014-01-22 Chanel Parfums Beauté Inhibitors of micro-rnas for use for preventing and/or attenuating skin ageing and/or for hydrating skin
KR20200028498A (ko) 2010-06-24 2020-03-16 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
HUE061596T2 (hu) 2011-07-15 2023-07-28 Boehringer Ingelheim Int Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP2854824A1 (en) * 2012-05-25 2015-04-08 Boehringer Ingelheim International GmbH Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
CN105219697A (zh) * 2014-07-04 2016-01-06 赫柏慧康生物科技无锡有限公司 一种人原代角质细胞分离制备的方法
EP3132809A1 (en) 2015-08-21 2017-02-22 Bioskinco GmbH Composition and products comprising senescent cells for use in tissue regeneration
US10668259B2 (en) 2015-10-21 2020-06-02 Materials Science Associates, LLC Metal oxide and polymer controlled delivery systems, sunscreens, treatments, and topical coating applicators
JP2019518428A (ja) * 2016-04-12 2019-07-04 ユニシテ エーファウ アクチェンゲゼルシャフト 体液試料からの細胞外小胞（ｅｖ）の単離
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
CN109055303A (zh) * 2018-09-12 2018-12-21 山东麦德克斯生物科技有限公司 一种皮肤组织的构建方法
RU2731065C1 (ru) * 2019-12-24 2020-08-28 Федеральное государственное бюджетное учреждение науки Институт биологии развития им. Н.К. Кольцова РАН (ИБР РАН) Состав криоконсерванта для длительного хранения первичных кератиноцитов

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016038A (en) * 1968-04-01 1977-04-05 Hayashibara Company Process for preparing maltoses from starches
US4016036A (en) 1975-11-14 1977-04-05 Massachusetts Institute Of Technology Process for serially culturing keratinocytes
IT1207525B (it) 1987-06-23 1989-05-25 Ist Naz Ric Sul Cancro Metodo per la preservazione difogli trapiantabili di epitelio coltivato in vitro vitale.
US5292655A (en) * 1990-01-29 1994-03-08 Wille Jr John J Method for the formation of a histologically-complete skin substitute
IT1248934B (it) 1990-06-01 1995-02-11 Fidia Spa Membrane forate biocompatibili,processi per la loro preparazione,loro impiego come supporto per la crescita in vitro di cellule epiteliali, pelli artificiali cosi' ottenute e loro impiego nei trapianti di pelle
US6585969B1 (en) 1991-11-20 2003-07-01 N. V. Innogenetics S.A. Non-viable keratinocyte cell composition or lysate for promoting wound healing
EP0970701B1 (en) * 1991-11-20 2005-10-26 Innogenetics N.V. Pellets derived from keratinocytes for use as wound healing substances
US5891617A (en) * 1993-09-15 1999-04-06 Organogenesis Inc. Cryopreservation of harvested skin and cultured skin or cornea equivalents by slow freezing
US5518878A (en) 1993-09-15 1996-05-21 Organogenesis Inc. Cryopreservation of cultured skin or cornea equivalents with agitation
US5693332C1 (en) 1995-08-11 2001-01-09 Univ California Human keratinocytes supported on a hydrophilic membrane and methods of using same to effect wound closure
AUPP244498A0 (en) 1998-03-18 1998-04-09 Medvet Science Pty. Ltd. Keratinocyte stem cells
DE19917532A1 (de) 1999-04-19 2000-10-26 Christian Toloczyki Trägergebundene kultivierte Stamm-bzw. Vorläuferzellen von Keratinozyten

Also Published As

Publication number Publication date
US20080131967A1 (en) 2008-06-05
AR036827A1 (es) 2004-10-06
WO2003033686A3 (de) 2004-02-12
NO20041570L (no) 2004-04-16
US20070065419A1 (en) 2007-03-22
HUP0600341A2 (en) 2006-08-28
EP1440148A2 (de) 2004-07-28
DE10151296A1 (de) 2003-04-30
HU228887B1 (hu) 2013-06-28
IL161442A (en) 2012-02-29
UA81398C2 (en) 2008-01-10
HRP20040347A2 (en) 2005-04-30
US7247478B2 (en) 2007-07-24
ATE474039T1 (de) 2010-07-15
UY27486A1 (es) 2003-05-30
DE50214540D1 (de) 2010-08-26
RS30104A (sr) 2006-10-27
PE20030627A1 (es) 2003-07-16
AU2002349352B2 (en) 2007-11-01
CA2461141A1 (en) 2003-04-24
ES2345767T3 (es) 2010-10-01
US7306943B2 (en) 2007-12-11
CA2461141C (en) 2011-12-06
EA009073B1 (ru) 2007-10-26
BR0213282A (pt) 2004-10-26
EP1440148B1 (de) 2010-07-14
WO2003033686A2 (de) 2003-04-24
HUP0600341A3 (en) 2011-03-28
ZA200402306B (en) 2006-05-31
PL367338A1 (en) 2005-02-21
CO5580844A2 (es) 2005-11-30
JP2005505392A (ja) 2005-02-24
MXPA04003487A (es) 2004-07-30
US20030091542A1 (en) 2003-05-15
MY137828A (en) 2009-03-31
KR101019916B1 (ko) 2011-03-08
HRP20040347B1 (en) 2012-07-31
US7754481B2 (en) 2010-07-13
DK1440148T3 (da) 2010-09-27
KR20040045856A (ko) 2004-06-02
EA200400482A1 (ru) 2004-12-30
IL161442A0 (en) 2004-09-27
NZ532899A (en) 2006-04-28
JP4476625B2 (ja) 2010-06-09
NO334974B1 (no) 2014-08-11
CN100432220C (zh) 2008-11-12
CN1571835A (zh) 2005-01-26

Similar Documents

Publication Publication Date Title
ECSP045065A (es) Queratinocitos utilizables como sustancia biológicamente activa en el tratamiento de heridas
MX2008000243A (es) Material de curacion para heridas.
BR0209292A (pt) Uso compostos de complexos de metais como catalisadores de oxidação
PE20030716A1 (es) Formas de sal e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi) fenilamino] quinazolin-6-il} alil) acetamida y procedimiento de produccion
PA8525201A1 (es) Tetrazolil-fenil acetamidas como activadores de la glucoquinasa
AR031975A1 (es) Compuestos analogos de (1r,cis)-4-(6-amino-9h-purin-9-il) -2-ciclopenteno-1-metanol, proceso para su preparacion, su uso en el tratamiento de infecciones virales, y envase que los contiene
AU2002349352A1 (en) Keratinocytes which may be used as biologically active substances for the treatment of wounds
GT200500363A (es) 3-amino-pirazol [3,4b] piridinas con inhibidores de proteintirosinquinasas, su preparacion y uso como medicamento.
ATE415817T1 (de) Agrochemische formulierungen
AU1922902A (en) Novel means for the diagnosis and therapy of CTCL
AU2002214389A1 (en) Pharmaceutical composition containing honey for the treatment of wounds
ITPD20050207A1 (it) Nuove composizioni farmaceutiche contenenti acido ialuronico e collagenas nel trattamento topico di ferite, ustioni ed ulcere
DE60230455D1 (de) Natürliche verbindung für die behandlung von diabetes, deren herstellung und verwendung
ATE307598T1 (de) Verwendung eines zyklischen ethers zur herstellung von mitteln, die die glukosetoleranz beeinflussen
WO2002024181A3 (en) The use of melatonin for induction of general anesthesia
UY29999A1 (es) "n-pirazinil-fenilsulfonamidas, procedimientos y compuestos intemedios utilizados en su preparacion, composiciones farmaceuticas que las contienen y aplicaciones"
ATE298328T1 (de) Taxan-derivate für die behandlung von krebs
SV2002000639A (es) Alcanosulfonatos de fenoxifenilo ref. lea 34813-sv
ES2192034T3 (es) Feniluracilos substituidos con efecto herbicida.
IS5231A (is) Vefjaþáttur sem hefur áhrif á blóðæðarmyndun
ATE275551T1 (de) Halogenpyrimidine
AU2006272424A8 (en) Homogemcitabines
TH60887A (th) เคราทิโนไซต์ซึ่งอาจใช้เป็นสารออกฤทธิ์เชิงชีวภาพในการรักษาบาดแผล
DE60335292D1 (de) 4-methylhexanoic kahalalide f verbindung
PT1194158E (pt) Uso da proteina uk 114 para inibir a rejeicao do transplante de orgaos